Obesity affects a large percentage of patients in the United States and is associated with increased mortality and higher healthcare costs. Newer guidelines recommend a minimum of 10% weight loss goal for patients with obesity, and medical management options fall short. Tirzepatide, the first available dual-incretin analog, is a novel treatment for type 2 diabetes that also can induce weight loss. This article discusses tirzepatide as a treatment for obesity.